Rohto Pharmaceutical Co.,Ltd. (FRA:UC1)

Rohto Pharmaceutical Statistics

Total Valuation

FRA:UC1 has a market cap or net worth of EUR 3.15 billion. The enterprise value is 3.08 billion.

Market Cap	3.15B
Enterprise Value	3.08B

Important Dates

The next estimated earnings date is Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	Sep 29, 2025

Share Statistics

Current Share Class	225.96M
Shares Outstanding	n/a
Shares Change (YoY)	+0.53%
Shares Change (QoQ)	+1.77%
Owned by Insiders (%)	2.22%
Owned by Institutions (%)	37.32%
Float	188.99M

Valuation Ratios

The trailing PE ratio is 15.31.

PE Ratio	15.31
Forward PE	n/a
PS Ratio	1.64
PB Ratio	1.87
P/TBV Ratio	2.64
P/FCF Ratio	17.26
P/OCF Ratio	13.35
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.95, with an EV/FCF ratio of 16.85.

EV / Earnings	14.94
EV / Sales	1.70
EV / EBITDA	9.95
EV / EBIT	14.09
EV / FCF	16.85

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.16.

Current Ratio	2.17
Quick Ratio	1.47
Debt / Equity	0.16
Debt / EBITDA	0.83
Debt / FCF	1.49
Interest Coverage	28.13

Financial Efficiency

Return on equity (ROE) is 12.90% and return on invested capital (ROIC) is 7.72%.

Return on Equity (ROE)	12.90%
Return on Assets (ROA)	5.90%
Return on Invested Capital (ROIC)	7.72%
Return on Capital Employed (ROCE)	11.86%
Revenue Per Employee	210,239
Profits Per Employee	22,508
Employee Count	9,144
Asset Turnover	0.79
Inventory Turnover	2.34

Taxes

In the past 12 months, FRA:UC1 has paid 65.58 million in taxes.

Income Tax	65.58M
Effective Tax Rate	24.07%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	13.53
200-Day Moving Average	n/a
Relative Strength Index (RSI)	53.29
Average Volume (20 Days)	10

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:UC1 had revenue of EUR 1.92 billion and earned 205.82 million in profits. Earnings per share was 0.89.

Revenue	1.92B
Gross Profit	1.08B
Operating Income	230.55M
Pretax Income	272.41M
Net Income	205.82M
EBITDA	327.16M
EBIT	230.55M
Earnings Per Share (EPS)	0.89

Balance Sheet

The company has 450.62 million in cash and 271.15 million in debt, giving a net cash position of 179.47 million.

Cash & Cash Equivalents	450.62M
Total Debt	271.15M
Net Cash	179.47M
Net Cash Per Share	n/a
Equity (Book Value)	1.68B
Book Value Per Share	7.01
Working Capital	690.82M

Cash Flow

In the last 12 months, operating cash flow was 236.05 million and capital expenditures -53.50 million, giving a free cash flow of 182.55 million.

Operating Cash Flow	236.05M
Capital Expenditures	-53.50M
Free Cash Flow	182.55M
FCF Per Share	n/a

Margins

Gross margin is 56.21%, with operating and profit margins of 11.99% and 10.71%.

Gross Margin	56.21%
Operating Margin	11.99%
Pretax Margin	14.17%
Profit Margin	10.71%
EBITDA Margin	17.02%
EBIT Margin	11.99%
FCF Margin	9.50%

Dividends & Yields

This stock pays an annual dividend of 20.12, which amounts to a dividend yield of 146.86%.

Dividend Per Share	20.12
Dividend Yield	146.86%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	22.86%
Buyback Yield	-0.53%
Shareholder Yield	146.33%
Earnings Yield	6.53%
FCF Yield	5.79%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:UC1 has an Altman Z-Score of 4.49 and a Piotroski F-Score of 6.

Altman Z-Score	4.49
Piotroski F-Score	6